**Supplemental Table 2. NY-ESO-1 Expression Levels at Screening by Tumor Type**

|  |  |  |
| --- | --- | --- |
|  | **Patients Screeneda, n** | **Patients positive for NY-ESO-1, n (%)** |
| **≥5% Positive** | **<5% Positiveb** | **Total**  |
| Sarcoma |  |  |  |  |
| Synovial sarcoma | 41 | 28 (68) | 3 (7) | 31 (76) |
| MRCL | 14 | 13 (93) | 0 | 13 (93) |
| Other sarcoma | 128 | 13 (10) | 15 (12) | 28 (22) |
| Ovarian | 76 | 5 (7) | 33 (43) | 38 (50) |
| Melanoma | 28 | 7 (25) | 12 (43) | 19 (68) |
| NSCLC | 30 | 4 (13) | 6 (20) | 10 (33) |

MRCL = myxoid/round cell liposarcoma; NSCLC = non-small cell lung cancer; NY-ESO-1 = New York Esophageal Squamous Cell Carcinoma-1.

a Two patients with breast cancer were also screened, but no NY-ESO-1 positivity was detected in either patient.

b Includes evidence of NY-ESO-1 expression up to <5%. Positive NY-ESO-1 expression was initially defined as ≥5% expression by IHC, amended to any tumor cell-specific positivity; NY-ESO-1 expression was not re-evaluated in patients screened prior to this amendment.